Free Trial

bioAffinity Technologies Q4 2023 Earnings Report

bioAffinity Technologies logo
$1.09 +0.83 (+319.23%)
As of 04/1/2025 04:00 PM Eastern

bioAffinity Technologies EPS Results

Actual EPS
-$0.26
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

bioAffinity Technologies Revenue Results

Actual Revenue
$2.21 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

bioAffinity Technologies Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

Remove Ads

bioAffinity Technologies Earnings Headlines

Trump Allies Confirm Exec Order 14024 Triggers Dollar Collapse
Executive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth, your savings, and your retirement. When the dollar collapses, your savings could disappear overnight. With Trump threatening Russia with more sanctions, Russia is rushing to finalize their BRICS payment system aimed to destroy the U.S dollar.
SA biotech plans big cuts to grow core company
See More bioAffinity Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like bioAffinity Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on bioAffinity Technologies and other key companies, straight to your email.

About bioAffinity Technologies

bioAffinity Technologies (NASDAQ:BIAF), a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.

View bioAffinity Technologies Profile

More Earnings Resources from MarketBeat